European Multicenter Validation of PCaVision: A Head-to-Head Diagnostic Accuracy Study Comparing Multiparametric Transrectal Ultrasound to MRI for Clinically Significant Prostate Cancer Detection
transrectal ultrasound of prostate (TRUS) with AI software algorithmMRI prostate
transrectal ultrasound of prostate (TRUS) with AI software algorithm: Transrectal ultrasound of prostate (TRUS) with AI software algorithm for detection of lesions suspected for prostate cancer
MRI prostate: MRI for detection of lesions suspected for prostate cancer
Study summary
The goal of this clinical trial is to learn if a new ultrasound-based imaging method (PCaVision) can accurately detect clinically significant prostate cancer in adult men (18 years and older) who are either undergoing initial evaluation or are already in active surveillance for prostate cancer. The main questions it aims to answer are:
* Does PCaVision detect clinically significant prostate cancer as accurately as MRI?
* Can some men safely avoid prostate biopsies based on PCaVision imaging results?
Researchers will compare PCaVision-guided biopsies to MRI-guided biopsies to see if PCaVision performs as well as MRI in identifying aggressive prostate cancers.
Participants will:
* Undergo both an MRI and a PCaVision ultrasound scan
* Receive targeted prostate biopsies based on any suspicious areas found in either scan
* Possibly have follow-up visits to monitor for biopsy-related side effects
Eligibility
Sex
MALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion criteria:
1. male
2. 18 years of age or older
3. scheduled for evaluation by prostate MRI due to:
* suspicious digital rectal examination (DRE) and/or
* Elevated serum PSA levels, or as part of active surveillance (AS) follow-up
4. Have provided written informed consent
Exclusion criteria:
1. Active urinary tract infection or prostatitis
2. A history of cardiac right-to-left shunt
3. Allergy to sulphur hexafluoride or any other ingredient in the ultrasound contrast agent SonoVue
4. Current treatment with dobutamine
5. Severe pulmonary hypertension (pulmonary artery pressure \> 90 mmHg), uncontrolled systemic hypertension, or respiratory distress syndrome
6. Any other contraindication to MRI or 3D mpUS imaging
7. Inability to understand the language of the patient information (i.e., language barrier)
8. Previous treatment with focal therapy for prostate cancer (e.g., HIFU, cryotherapy, laser ablation, etc.)
Primary outcome measure(s)
Number of Participants With Clinically Significant Prostate Cancer (csPCa) Detected by PCaVision-Targeted Biopsies Compared to MRI-Targeted Biopsies — 12 months Clinically significant prostate cancer (csPCa) is defined as ISUP Grade Group (GG) ≥ 2. The number of participants in whom csPCa is detected through PCaVision-targeted biopsies will be compared to the number of participants with csPCa detected through MRI-targeted biopsies. The comparison will be performed separately for two patient cohorts:
1. Biopsy-naïve or prior negative biopsy patients
2. Patients under active surveillance (AS) A non-inferiority margin of 5 percentage points will be used.
Trial sites (10)
Facility
City
Region
Status
Institut Paoli- Calmettes
Marseille
France
L'Institut Mutualiste Montsouris
Paris
France
University Klinikum Bonn
Bonn
Germany
Martini-Klinik am UKE
Hamburg
Germany
Urologische Klinik München- Planegg
Planegg
Germany
Università degli Studi di Foggia
Foggia
Italy
University of Padua
Padova
Italy
Amsterdam UMC
Amsterdam
Netherlands
Oslo University hospital Ullevål
Oslo
Norway
Fundació Puigvert
Barcelona
Spain
More Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) trials in Germany
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.